bronchodilator agents

Summary

Summary: Agents that cause an increase in the expansion of a bronchus or bronchial tubes.

Top Publications

  1. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
  2. ncbi A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    Donald P Tashkin
    David Geffen School of Medicine at the University of California, Los Angeles 90095 1690, USA
    N Engl J Med 359:1543-54. 2008
  3. ncbi Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society
    Amir Qaseem
    American College of Physicians and Temple University, Philadelphia, Pennsylvania 19106, USA
    Ann Intern Med 155:179-91. 2011
  4. ncbi Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison
    Donald A Mahler
    Section of Pulmonary and Critical Care Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
    Thorax 67:781-8. 2012
  5. pmc Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
    Edward Kerwin
    Clinical Research Institute of Southern Oregon, PC, Medford, OR, USA
    Eur Respir J 40:1106-14. 2012
  6. ncbi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
  7. ncbi Outcomes for COPD pharmacological trials: from lung function to biomarkers
    M Cazzola
    Unit of Respiratory Diseases, Dept of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Eur Respir J 31:416-69. 2008
  8. ncbi Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
    Ronald Dahl
    Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
    Thorax 65:473-9. 2010
  9. ncbi Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
    O Kornmann
    Pulmonary Division, Internal Medicine, University Hospital, Mainz, Germany
    Eur Respir J 37:273-9. 2011
  10. ncbi Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial
    Marc Decramer
    Respiratory Division, University of Leuven, Leuven, Belgium
    Lancet 374:1171-8. 2009

Detail Information

Publications303 found, 100 shown here

  1. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
    ..Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown...
  2. ncbi A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    Donald P Tashkin
    David Geffen School of Medicine at the University of California, Los Angeles 90095 1690, USA
    N Engl J Med 359:1543-54. 2008
    ..Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term effects of tiotropium therapy...
  3. ncbi Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society
    Amir Qaseem
    American College of Physicians and Temple University, Philadelphia, Pennsylvania 19106, USA
    Ann Intern Med 155:179-91. 2011
    ....
  4. ncbi Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison
    Donald A Mahler
    Section of Pulmonary and Critical Care Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
    Thorax 67:781-8. 2012
    ..The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily long-acting β(2) agonist, and the long-acting muscarinic antagonist tiotropium, compared with tiotropium alone...
  5. pmc Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
    Edward Kerwin
    Clinical Research Institute of Southern Oregon, PC, Medford, OR, USA
    Eur Respir J 40:1106-14. 2012
    ..NVA237 can potentially be an alternative choice of LAMA for COPD patients...
  6. ncbi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
    ..Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD)...
  7. ncbi Outcomes for COPD pharmacological trials: from lung function to biomarkers
    M Cazzola
    Unit of Respiratory Diseases, Dept of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Eur Respir J 31:416-69. 2008
    ..Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations...
  8. ncbi Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
    Ronald Dahl
    Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
    Thorax 65:473-9. 2010
    ..In previous studies, indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action. This study compared the efficacy and safety of indacaterol with the twice-daily LABA formoterol and placebo over 1 year...
  9. ncbi Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
    O Kornmann
    Pulmonary Division, Internal Medicine, University Hospital, Mainz, Germany
    Eur Respir J 37:273-9. 2011
    ..Indacaterol should prove a useful additional treatment for patients with COPD...
  10. ncbi Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial
    Marc Decramer
    Respiratory Division, University of Leuven, Leuven, Belgium
    Lancet 374:1171-8. 2009
    ..However, there are few data for treatment in the early stages of the disease. We examined the effect of tiotropium on outcomes in a large subgroup of patients with moderate COPD...
  11. ncbi Tiotropium versus salmeterol for the prevention of exacerbations of COPD
    Claus Vogelmeier
    Hospital of the Universities of Giessen and Marburg, Marburg, Germany
    N Engl J Med 364:1093-1103. 2011
    ..We investigated whether the anticholinergic drug tiotropium is superior to the β(2)-agonist salmeterol in preventing exacerbations of COPD...
  12. ncbi Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
    Paul W Jones
    St George s, University of London, Cranmer Terrace, London, SW17 0RE, UK
    Eur Respir J 40:830-6. 2012
    ..Twice-daily aclidinium significantly improved bronchodilation, health status and dyspnoea, and was well tolerated in patients with COPD...
  13. ncbi Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials
    Yaa Hui Dong
    Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
    Thorax 68:48-56. 2013
    ..We aimed to compare the risk of overall and cardiovascular death for inhaled medications in patients with COPD...
  14. ncbi Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
    Ruth H Green
    Institute for Lung Health, Department of Respiratory Medicine and Thoracic Surgery, Glenfield Hospital, LE3 9PQ, Leicester, UK
    Lancet 360:1715-21. 2002
    ..We aimed to assess whether a management strategy that minimises eosinophilic inflammation reduces asthma exacerbations compared with a standard management strategy...
  15. ncbi COPD exacerbations: defining their cause and prevention
    Jadwiga A Wedzicha
    Academic Unit of Respiratory Medicine, Royal Free and University College Medical School University College London, UK
    Lancet 370:786-96. 2007
    ....
  16. ncbi Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
    R Buhl
    Pulmonary Department, Mainz University Hospital, Langenbeckstrasse 1, Mainz, D 55131, Germany
    Eur Respir J 38:797-803. 2011
    ..Both bronchodilators demonstrated spirometric efficacy. The two treatments were well tolerated with similar adverse event profiles. Compared with tiotropium, indacaterol provided significantly greater improvements in clinical outcomes...
  17. ncbi Tiotropium versus placebo for chronic obstructive pulmonary disease
    Charlotta Karner
    Population Health Sciences and Education, St George s, University of London, London, UK
    Cochrane Database Syst Rev 7:CD009285. 2012
    ....
  18. ncbi Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
    Leonardo M Fabbri
    University of Modena and Reggio Emilia, Modena, Italy
    Lancet 374:695-703. 2009
    ..The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated...
  19. ncbi Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review
    Gustavo J Rodrigo
    Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, 11300 Uruguay
    Chest 142:1104-10. 2012
    ..Bronchodilators are central to the symptomatic management of patients with COPD.Previous data have shown that inhaled indacaterol improved numerous clinical outcomes over placebo...
  20. pmc Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA, USA
    BMC Pulm Med 12:29. 2012
    ....
  21. ncbi Pharmacology and therapeutics of bronchodilators
    Mario Cazzola
    Universita di Roma Tor Vergata, Dipartimento di Medicina Interna, Via Montpellier 1, 00133 Roma, Italy
    Pharmacol Rev 64:450-504. 2012
    ..This review will describe the pharmacology and therapeutics of old, new, and emerging classes of bronchodilator...
  22. ncbi Effect of indacaterol on exercise endurance and lung hyperinflation in COPD
    Denis E O'Donnell
    Queen s University and Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada
    Respir Med 105:1030-6. 2011
    ..This study investigated the effect of indacaterol on exercise endurance, and on lung hyperinflation during exercise and at rest in patients with moderate-to-severe COPD...
  23. ncbi Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study
    Bartolome R Celli
    Tufts University School of Medicine, Pulmonary and Critical Care Division, Caritas St Elizabeth s Medical Center, Boston, MA 02135 2997, USA
    Am J Respir Crit Care Med 178:332-8. 2008
    ..Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated decline in lung function. No drug has been shown conclusively to reduce this decline...
  24. pmc Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
    Christine R Jenkins
    Woolcock Institute of Medical Research, Sydney, Australia
    Respir Res 10:59. 2009
    ..However, there are only limited data about the influence of GOLD severity staging on the effectiveness of SFC, particularly in patients with milder disease...
  25. ncbi Symptom variability in patients with severe COPD: a pan-European cross-sectional study
    R Kessler
    Dept of PneumologyNouvel Hôpital Civil, Strasbourg 67000, France
    Eur Respir J 37:264-72. 2011
    ..Patient-perceived COPD symptoms vary over the day and the week, and impact on daily activities; morning being the worst time of day. The majority of patients appear not to adjust treatment when symptoms worsen...
  26. ncbi Adherence to inhaled therapy, mortality and hospital admission in COPD
    J Vestbo
    Respiratory Medicine Research Group, University of Manchester, Manchester, UK
    Thorax 64:939-43. 2009
    ..Little is known about adherence to inhaled medication in chronic obstructive pulmonary disease (COPD) and the impact on mortality and morbidity...
  27. ncbi Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies
    Edward M Kerwin
    Clinical Research Institute of Southern Oregon PC, Medford, Oregon 97504, USA
    Clin Ther 33:1974-84. 2011
    ....
  28. ncbi Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients
    R M Mroz
    Department of Lung Diseases, Medical University of Bialystok, Zurawia 14, Bialystok, Poland
    Adv Exp Med Biol 756:23-8. 2013
    ..The patients' quality of life also changed favorably in the indacaterol treatment arm. We conclude that the add-on therapy with indacaterol exerts positive effects in COPD patients...
  29. ncbi Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes
    Thys van der Molen
    Department of General Practice, University Medical Center Groningen, Groningen, The Netherlands
    Prim Care Respir J 21:101-8. 2012
    ....
  30. ncbi Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study
    Claus Vogelmeier
    Klinik für Innere Medizin mit Schwerpunkt Pneumologie, Universitätsklinikum Giessen und Marburg, Standort Marburg Baldingerstrasse, D 35043 Marburg, Germany
    Respir Med 102:1511-20. 2008
    ..Combined bronchodilator therapy may be a valuable treatment option for patients with COPD...
  31. ncbi QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Thorax 65:1086-91. 2010
    ....
  32. ncbi Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD
    Federico Lavorini
    Unità Funzionale di Medicina Respiratoria, Universita degli Studi di Firenze, Italy
    Respir Med 102:593-604. 2008
    ..Incorrect usage of inhaler devices might have a major influence on the clinical effectiveness of the delivered drug. This issue is poorly addressed in management guidelines...
  33. ncbi The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 23:257-67. 2010
    ....
  34. ncbi Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study
    Stephanie Korn
    Pulmonary Department, Mainz University Hospital, Mainz, Germany
    Respir Med 105:719-26. 2011
    ..Indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of COPD...
  35. ncbi Impact of preventing exacerbations on deterioration of health status in COPD
    S Spencer
    Dept of Health and Social Care, Brunel University, Isleworth, UK
    Eur Respir J 23:698-702. 2004
    ..Statistical modelling showed the beneficial effect of fluticasone propionate on deterioration in health status to be largely due to its effect on exacerbation frequency...
  36. ncbi Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Eur Respir J 26:214-22. 2005
    ..i.d. A combination of both drugs q.d. was most effective and provided an additive effect throughout the 24-h dosing interval...
  37. pmc Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
    Didier Renard
    Novartis Pharma AG, Basel, Switzerland
    Respir Res 12:54. 2011
    ..We considered alternative methods of analysis...
  38. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
    ..The combination of short-acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented, but data on combination of long-acting agents are lacking...
  39. ncbi Hospitalizations and mortality in the Lung Health Study
    Nicholas R Anthonisen
    University of Manitoba, Winnipeg, Manitoba, Canada
    Am J Respir Crit Care Med 166:333-9. 2002
    ..When all participants were considered and smoking status considered as a time-dependent covariate, smoking cessation was associated with significant reductions in fatal or nonfatal cardiovascular disease and coronary artery disease...
  40. ncbi Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study
    P D Scanlon
    Division of Pulmonary and Critical Care Medicine, Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Respir Crit Care Med 161:381-90. 2000
    ..Respiratory symptoms were not predictive of changes in lung function. Smokers with airflow obstruction benefit from quitting despite previous heavy smoking, advanced age, poor baseline lung function, or airway hyperresponsiveness...
  41. ncbi Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Respir Med 104:995-1004. 2010
    ..Clinical information on 24-h spirometric efficacy of combining tiotropium and salmeterol compared to single-agent therapy is lacking in patients with COPD...
  42. pmc Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials
    Sonal Singh
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA
    BMJ 342:d3215. 2011
    ..To systematically review the risk of mortality associated with long term use of tiotropium delivered using a mist inhaler for symptomatic improvement in chronic obstructive pulmonary disease...
  43. ncbi Bronchodilator responsiveness in patients with COPD
    D P Tashkin
    David Geffen School of Medicine, UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90024, USA
    Eur Respir J 31:742-50. 2008
    ..The majority of patients with moderate-to-very-severe chronic obstructive pulmonary disease demonstrate meaningful increases in lung function following administration of inhaled anticholinergic plus sympathomimetic bronchodilators...
  44. pmc Safety of indacaterol in the treatment of patients with COPD
    James F Donohue
    University of North Carolina, Chapel Hill, NC 27599, USA
    Int J Chron Obstruct Pulmon Dis 6:477-92. 2011
    ..Pooled data were analyzed to evaluate the safety and tolerability of indacaterol, a once-daily inhaled long-acting β(2)-agonist for chronic obstructive pulmonary disease (COPD)...
  45. ncbi Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease
    D E O'Donnell
    Respiratory Investigation Unit, Dept of Medicine, Queen s University, Kingston, Canada
    Eur Respir J 24:86-94. 2004
    ..Bronchodilator-induced lung deflation reduced mechanical restriction, increased ventilatory capacity and decreased respiratory discomfort, thereby increasing exercise endurance...
  46. pmc Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
    Donald P Tashkin
    David Geffen School of Medicine, Division of Pulmonary and Critical Care Medicine, UCLA, Los Angeles, California, USA
    Respir Res 11:149. 2010
    ..Once-daily LABAs used both alone and in combination with long-acting muscarinic antagonists represent a promising advance in the treatment of COPD, and are likely to further improve outcomes for patients...
  47. ncbi Minimal important difference of the transition dyspnoea index in a multinational clinical trial
    T J Witek
    Respiratory Development and Operations, Boehringer Ingelheim GmbH Ingelheim am Rhein, Germany
    Eur Respir J 21:267-72. 2003
    ....
  48. pmc Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit
    Rupert C M Jones
    Respiratory Research Unit, Peninsula Medical School, 1 Davy Road, Plymouth, UK
    Respir Res 9:62. 2008
    ..These lead to inaccurate diagnostic registers and inadequacy of administered treatments. This study represents an audit of COPD diagnosis and management in primary care practices in Devon...
  49. pmc Gender and chronic obstructive pulmonary disease: why it matters
    MeiLan K Han
    Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA
    Am J Respir Crit Care Med 176:1179-84. 2007
    ....
  50. pmc Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial
    Stephen I Rennard
    Pulmonary Critical Care, Allergy and Sleep Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 5885, USA
    Drugs 69:549-65. 2009
    ....
  51. pmc Muscarinic receptor signaling in the pathophysiology of asthma and COPD
    Reinoud Gosens
    Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
    Respir Res 7:73. 2006
    ....
  52. ncbi Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium
    Andrea Rossi
    Unità Operativa Complessa di Pneumologia, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
    Respir Med 106:84-90. 2012
    ..Evidence has been provided that high-dose indacaterol (300 μg) can reduce lung hyperinflation in moderate-to-severe chronic obstructive pulmonary disease (COPD)...
  53. ncbi Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Value Health 15:524-33. 2012
    ..Indacaterol trial evidence was synthesized to provide coherent estimates of indacaterol 150 μg and indacaterol 300 μg relative to formoterol, salmeterol, and tiotropium...
  54. pmc Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium
    Kai Michael Beeh
    insaf Respiratory Research Institute, Wiesbaden, Germany
    Respir Res 13:52. 2012
    ....
  55. pmc Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis
    Paul W Jones
    Division of Clinical Science, St George s, University of London, London, UK
    Respir Res 12:161. 2011
    ..We examined whether changes in trough forced expiratory volume in 1 second (FEV(1)) are correlated with changes in patient-reported outcomes...
  56. ncbi Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes
    Abebaw Mengistu Yohannes
    Department of Health Professions, Manchester Metropolitan University, Manchester, United Kingdom, UK
    Respir Care 56:477-87. 2011
    ....
  57. ncbi Night-time symptoms: a forgotten dimension of COPD
    A Agusti
    Thorax Institute, Hospital Clinic, IDIBAPS, Villaroel 1170, Barcelona, Spain
    Eur Respir Rev 20:183-94. 2011
    ..In summary, night-time symptoms in COPD warrant further clinical investigation with validated tools...
  58. ncbi The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease
    Kai M Beeh
    insaf Respiratory Research Institute, Wiesbaden, Germany
    Adv Ther 27:150-9. 2010
    ....
  59. ncbi Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
    C Verkindre
    Hopital de Bethune, Beuvry, France
    Respir Med 104:1482-9. 2010
    ..All doses of NVA237 and tiotropium were well tolerated. NVA237 once-daily was effective and well tolerated versus placebo, and demonstrated rapid and sustained 24-h bronchodilation. (ClinicalTrials.gov Identifier: NCT00501852)...
  60. ncbi Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease
    Jimmy Chong
    University of Auckland, Auckland, New Zealand
    Cochrane Database Syst Rev 9:CD009157. 2012
    ..There are new studies which have compared tiotropium with LABAs, including some that have evaluated recently introduced LABAs...
  61. ncbi Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients
    Boudewijn Van de Maele
    AZ Sint Jan Brugge Oostende AV, Campus H Serruys, Oostende, Belgium
    COPD 7:418-27. 2010
    ..Once-daily QVA149 was well tolerated in COPD patients with a cardiovascular safety profile and overall adverse event rates similar to placebo...
  62. ncbi Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial
    Donald P Tashkin
    Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, California, USA
    Drugs 68:1975-2000. 2008
    ..Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patients with COPD...
  63. pmc Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial
    Jean Bourbeau
    Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada
    Thorax 62:938-43. 2007
    ..A study was therefore undertaken to evaluate combined salmeterol/fluticasone propionate (SFC) and fluticasone propionate (FP) alone on inflammatory cells in the airways of patients with COPD...
  64. ncbi Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD
    Heinrich Worth
    Medical Department I, Klinikum Fürth, Jakob Henle Str 1, D 90766 Fürth, Germany
    Respir Med 105:571-9. 2011
    ..As COPD patients commonly suffer cardio- and cerebrovascular (CCV) co-morbidities, our purpose was to establish the CCV safety profile of indacaterol, a novel, inhaled, long-acting β(2)-agonist for COPD...
  65. ncbi What have we learned from large drug treatment trials in COPD?
    Peter M A Calverley
    Division of Infection and Immunity, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Lancet 370:774-85. 2007
    ..Ensuring that these expensive studies are done objectively to the highest standard is an important goal for the next decade...
  66. ncbi Histone acetylation and deacetylation: importance in inflammatory lung diseases
    P J Barnes
    National Heart and Lung Institute, Imperial College, London SW3 6LY, UK
    Eur Respir J 25:552-63. 2005
    ..The reduction in histone deacetylase activity can be restored by theophylline, which may be able to reverse steroid resistance in chronic obstructive pulmonary disease and other inflammatory diseases...
  67. ncbi Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease
    Kristen E Belmonte
    Respiratory and Inflammation Centre of Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA, USA
    Proc Am Thorac Soc 2:297-304; discussion 311-2. 2005
    ..Adequate concurrent blockade of M3 muscarinic receptors would be expected to counteract the enhanced acetylcholine release that would result from blockade of neuronal inhibitory M2 muscarinic receptors...
  68. ncbi Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes
    Antonio Anzueto
    University of Texas Health Science Center at San Antonio, San Antonio, TX, 78230, USA
    COPD 6:320-9. 2009
    ..2%). FSC 250/50 is more effective than SAL at reducing the rate of moderate/severe exacerbations. These data confirm the beneficial effect of FSC on the management of COPD exacerbations and support the use of FSC in patients with COPD...
  69. ncbi Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial
    Thérèse S Lapperre
    Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
    Ann Intern Med 151:517-27. 2009
    ..Inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) are used to treat moderate to severe chronic obstructive pulmonary disease (COPD)...
  70. ncbi Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations
    Gary T Ferguson
    Pulmonary Research Institute of SouthEast Michigan, 28807 Eight Mile Road, Suite 103, Livonia, MI 48152, USA
    Respir Med 102:1099-108. 2008
    ..This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations...
  71. ncbi Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history
    E D Bateman
    University of Cape Town Lung Institute, Cape Town, South Africa
    Eur Respir J 38:553-60. 2011
    ..No differences arose in adverse events between these subgroups. Roflumilast may be used to reduce exacerbations and improve dyspnoea and lung function, without increasing adverse events in COPD patients receiving concomitant LABAs...
  72. ncbi Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD
    Francois Maltais
    Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Universite Laval, 2725 Chemin Sainte Foy, Quebec G1V 4G5, Canada
    Respir Med 105:580-7. 2011
    ..Static and dynamic lung hyperinflation are associated with exercise impairment and poor outcomes in COPD patients. Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently in development for COPD treatment...
  73. ncbi Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
    C Vogelmeier
    Universitätsklinikum Giessen und Marburg, Marburg, Germany
    Pulm Pharmacol Ther 23:438-44. 2010
    ..Overall, the present study provides further evidence of the safety, tolerability and bronchodilator efficacy of once-daily treatment with NVA237 100 and 200 microg in patients with moderate-to-severe COPD...
  74. ncbi Cardiovascular events in patients with COPD: TORCH study results
    Peter M A Calverley
    Department of Medicine, University Hospital Aintree, Longmoor Lane, Liverpool, UK
    Thorax 65:719-25. 2010
    ....
  75. ncbi Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
    Peter J Barnes
    Imperial College, London, UK
    Pulm Pharmacol Ther 23:165-71. 2010
    ..This approach was used in a clinical study of indacaterol, a novel once-daily (od) inhaled long-acting beta(2)-adrenoreceptor agonist bronchodilator for the treatment of COPD (chronic obstructive pulmonary disease)...
  76. ncbi Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD
    Denis E O'Donnell
    Queen s University, Kingston, ON, Canada
    Chest 130:647-56. 2006
    ..To examine the effect of fluticasone propionate, 250 microg/salmeterol, 50 microg combination (FSC 250/50) twice daily on lung hyperinflation and associated measures of exercise performance in patients with COPD...
  77. ncbi Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD
    Bartolome R Celli
    Harvard University, Brigham and Women s Hospital, Pulmonary and Critical Care Medicine, Boston, MA 02115, USA
    Respir Med 105:1176-88. 2011
    ..We also evaluated the speed of onset of bronchodilation...
  78. pmc Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis
    Shannon Cope
    Mapi Values, Boston, MA, USA
    Int J Chron Obstruct Pulmon Dis 6:329-44. 2011
    ....
  79. ncbi Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD
    Rainard Fuhr
    Early Phase Clinical Unit Berlin, PAREXEL International GmbH, Berlin, Germany
    Chest 141:745-52. 2012
    ..The efficacy and safety of aclidinium bromide bid, a novel, long-acting, muscarinic antagonist, was assessed in patients with moderate to severe COPD...
  80. ncbi Chemical composition and mechanisms underlying the spasmolytic and bronchodilatory properties of the essential oil of Nepeta cataria L
    Anwar H Gilani
    Drug Discovery and Natural Products Research Unit, Department of Biological and Biomedical Sciences, The Aga Khan University Medical College, Karachi 74800, Pakistan
    J Ethnopharmacol 121:405-11. 2009
    ..The study was aimed to investigate the chemical composition and pharmacological basis for traditional use of essential oil of Nepeta cataria L. (Limiaceae) (Nc.Oil) in gastrointestinal and respiratory disorders...
  81. pmc Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: cluster randomised controlled trial
    Yumin Zhou
    State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
    BMJ 341:c6387. 2010
    ..To evaluate the effects of a community based integrated intervention for early prevention and management of chronic obstructive pulmonary disease (COPD) in China...
  82. pmc The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial
    Chris Dalby
    Respiratory Medicine Unit, City Hospital Campus, Nottingham University, Nottingham, UK
    Respir Res 10:104. 2009
    ....
  83. ncbi Prevention of exacerbations of COPD with pharmacotherapy
    M Miravitlles
    Servei de Pneumologia, Hospital Clinic, Villarroel 170, Barcelona, Spain
    Eur Respir Rev 19:119-26. 2010
    ....
  84. pmc Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
    Luis Javier Nannini
    Pulmonary Section, Hospital E Peron, G Baigorria, Argentina
    Cochrane Database Syst Rev 9:CD006829. 2012
    ..This updated review compared compound LABA plus ICS therapy (LABA/ICS) with the LABA component drug given alone...
  85. pmc Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease
    J Vestbo
    North West Lung Centre, Wythenshawe Hospital, Manchester M23 9LT, UK
    Thorax 60:301-4. 2005
    ..Combined treatment with inhaled corticosteroids and long acting beta2 agonists is approved for the treatment of chronic obstructive pulmonary disease (COPD), but little is known about the onset of effect of the combination...
  86. pmc Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD
    Kenneth R Chapman
    Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    Int J Chron Obstruct Pulmon Dis 6:353-63. 2011
    ..These are important factors for optimum dose delivery and successful COPD management...
  87. pmc Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
    Michael W Sims
    Pulmonary, Allergy, and Critical Care Division, Airways Biology Initiative, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Int J Chron Obstruct Pulmon Dis 6:457-66. 2011
    ..This article will provide a pharmacologic profile of aclidinium bromide and review the preclinical and clinical studies evaluating its safety and efficacy in the treatment of COPD...
  88. ncbi NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease
    Claus Vogelmeier
    Department for Respiratory Diseases, University of Marburg, Baldingerstrasse, 35033 Marburg, Germany
    Ther Adv Respir Dis 5:163-73. 2011
    ..Phase III studies are ongoing that will assess the long-term safety and efficacy of NVA237...
  89. ncbi Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease
    D E O'Donnell
    Respiratory Investigation Unit, Departments of Medicine, and Community Health and Epidemiology, Queen s University, Kingston, Ontario, Canada
    Am J Respir Crit Care Med 158:1557-65. 1998
    ..35, p < 0.001). We concluded that Borg dyspnea ratings, and measurements of IC and endurance time during submaximal cycle exercise testing are highly reproducible and responsive to change in severe COPD...
  90. pmc Impact of bronchodilator therapy on exercise tolerance in COPD
    B Aguilaniu
    HYLAB, Laboratory of Clinical Physiology and Exercise, Grenoble, France
    Int J Chron Obstruct Pulmon Dis 5:57-71. 2010
    ..However, further studies should confirm the benefit of long-acting bronchodilators in improving spontaneous everyday physical activities...
  91. ncbi Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol
    Lizbet Todorova
    Department of Cell and Molecular Biology, Lund University, Lund, Sweden
    Am J Respir Cell Mol Biol 34:92-100. 2006
    ..In conclusion, the proteoglycan upregulation characteristic of asthmatic airways may be limited by combination therapy with budesonide and formoterol...
  92. pmc Optimising treatment for COPD--new strategies for combination therapy
    T Welte
    Department of Respiratory Medicine, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Int J Clin Pract 63:1136-49. 2009
    ....
  93. ncbi Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
    Johannes M A Daniels
    Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Am J Respir Crit Care Med 181:150-7. 2010
    ..The role of antibiotics in acute exacerbations is controversial and their efficacy when added to systemic corticosteroids is unknown...
  94. ncbi Epinephrine and dexamethasone in children with bronchiolitis
    Amy C Plint
    Department of Pediatrics, University of Ottawa and Children s Hospital of Eastern Ontario, Ottawa, Canada
    N Engl J Med 360:2079-89. 2009
    ..Although numerous studies have explored the benefit of using nebulized epinephrine or corticosteroids alone to treat infants with bronchiolitis, the effectiveness of combining these medications is not well established...
  95. ncbi Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study
    E D Bateman
    Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Allergy 63:932-8. 2008
    ....
  96. ncbi A one-year trial of tiotropium Respimat plus usual therapy in COPD patients
    E D Bateman
    Division of Pulmonology, Department of Medicine, University of Cape Town, Mowbray, Cape Town, South Africa
    Respir Med 104:1460-72. 2010
    ..The protocol is registered on the European Clinical Trials Database as trial number 2006-001009-27 and in the ClinicalTrials.gov database as NCT00387088...
  97. pmc Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma
    Jorge F Maspero
    Fundacion CIDEA, Allergy Respiratory Research, Buenos Aires, Argentina
    J Asthma 47:1106-15. 2010
    ..This study was conducted to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) administered through metered-dose inhaler (MDI) in patients with persistent asthma previously on medium- to high-dose ICS...
  98. ncbi Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy
    M Weatherall
    University of Otago Wellington, Wellington, New Zealand
    Thorax 65:39-43. 2010
    ..There is concern that long-acting beta agonist (LABA) drugs may increase the risk of asthma mortality...
  99. ncbi Aclidinium bromide provides long-acting bronchodilation in patients with COPD
    P Chanez
    Universite de la Mediterranee, Departement des Maladies Respiratoires, AP HM, 270 Boulevard de Sainte Marguerite, F 13009 Marseille, France
    Pulm Pharmacol Ther 23:15-21. 2010
    ..Aclidinium produced sustained bronchodilation over 24h and was well tolerated during this short-term study. Based on these data, aclidinium 200microg was selected as the investigational dose for future clinical trials in COPD...
  100. pmc Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies
    Eric Bateman
    Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Int J Chron Obstruct Pulmon Dis 5:197-208. 2010
    ..Tiotropium Respimat SMI 5 microg demonstrated sustained improvements in patients with COPD relative to placebo and similar to the 10 microg dose but with a lower frequency of anticholinergic adverse events...
  101. ncbi EP(2) receptor mediates bronchodilation by PGE(2) in mice
    J R Sheller
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Appl Physiol (1985) 88:2214-8. 2000
    ..06) but increased it in EP(2)(-/-) mice (from 0.73 +/- 0. 08 to 1.27 +/- 0.19). Similar results were obtained in mechanically ventilated mice. These data indicate that the EP(2) receptor mediates the bronchodilation effect of PGE(2)...

Research Grants62

  1. CIRCADIAN-COUPLED CELLULAR AND LUNG FUNCTION IN COPD
    Irfan Rahman; Fiscal Year: 2012
    ..End of Abstract) ..
  2. Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia
    Aaron Hamvas; Fiscal Year: 2013
    ..Identifying the role that these bacteria play will permit early treatment in an effort to prevent the development of these lung problems. (End of Abstract) ..
  3. The Efficacy of Pranayama in COPD
    David A Kaminsky; Fiscal Year: 2013
    ..The data from this study will provide fundamental new insights into the mechanisms of action of pranayama, and will be critical in designing a large, multicenter trial to test the effectiveness of pranayama in patients with COPD. ..
  4. Bronchodilator Effects of Toll-Like Receptor-7 Agonists.
    David B Jacoby; Fiscal Year: 2011
    ..abstract_text> ..
  5. BIOCHEMICAL PATHWAYS OF 12-HETE AND 12-KETE METABOLISM
    Joshua Rokach; Fiscal Year: 2010
    ..It is likely that these eosinophils are responsible for late phase asthma or inflammatory asthma. We plan to develop agents that will stop the infiltration of these cells into the lung and prevent inflammatory asthma. ..
  6. Cellular and Molecular Mechanisms of bitter tastant-induced bronchodilation
    Ronghua Zhuge; Fiscal Year: 2013
    ..Such advances will deepen our understanding of ASM biology and facilitate the development of bitter tastants as new bronchodilators. ..
  7. CLINICAL CENTER FOR MONITORING HEALTH IN WTC RESPONDERS
    IRIS G UDASIN; Fiscal Year: 2012
    ..Data will be collected on the electronic medical record system, Logician, and will be integrated with the data collected at the Data Collection Center. ..
  8. Development of anti-human TL1A monoclonal antibody for the treatment of human ast
    Vadim V Deyev; Fiscal Year: 2010
    ....
  9. Oxidative Stress and Anti-Inflammatory Lipids in Airway Disease
    Bruce D Levy; Fiscal Year: 2010
    ..In this proposal, we seek to develop a better understanding of the natural biological processes invoked during airway infection and inflammation that dysregulate the natural homeostatic mechanisms. (End of Abstract) ..
  10. Comparative effectiveness research in acute exacerbation of COPD
    Chu Lin Tsai; Fiscal Year: 2011
    ....
  11. Novel Molecular Mechanisms Promote GPCR-Induced Bronchodilation in Asthma
    REYNOLD ALEXANDER PANETTIERI; Fiscal Year: 2013
    ..abstract_text> ..
  12. Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol in Mild Asthma
    Nicola A Hanania; Fiscal Year: 2013
    ..Safety measures collected throughout the study will include adverse events (AEs), withdrawals due to AEs, serious AEs, pulmonary function measurements, vital signs, and physical examinations. ..
  13. Implementation and Outcomes of Noninvasive Ventilation in COPD
    Peter K Lindenauer; Fiscal Year: 2013
    ....
  14. Targeting actin dynamics to inhibit airway hypperresponsiveness and inflammation
    Robert S Tepper; Fiscal Year: 2013
    ....
  15. Beta Andrenergic Receptor Structure and Desensitization
    Richard B Clark; Fiscal Year: 2010
    ..abstract_text> ..
  16. CD23-mediated immunotherapy on airway inflammation
    Xiaoping Zhu; Fiscal Year: 2013
    ..These studies, therefore, are very likely to lead to greatly improved novel therapies that protect against and potentially cure asthma and allergic diseases. ..
  17. AIRWAY PHARMACOLOGY DURING ONTOGENESIS
    James Douglas; Fiscal Year: 1993
    ..to determine the mechanism(s) responsible for the changes in airway reactivity to bronchoconstrictor and bronchodilator agents which occurs during maturation...
  18. THORACOABDOMINAL ASYNCHRONY IN INFANT AIRWAY OBSTRUCTION
    Julian Allen; Fiscal Year: 1992
    ..motion? 3) Conversely, does resistive loaded breathing in normal infants lead to more asynchronous chest wall motion? 4) How do gestational and postnatal age affect the relationship between lung mechanics and thoraco-abdominal asynchrony?..
  19. TOPICAL B-BLOCKER SIDE EFFECTS IN ELDERLY
    JEROME AVORN; Fiscal Year: 1990
    ..difference between betaxolol and timolol in regard to the outcomes studied? (4) If differences in adverse effect risk are found in patients using these medications, what are its implications for practice in the care of glaucoma patients?..
  20. Volatile Anesthesic Inhibition of Ca2+ Release in Airway
    Gary Sieck; Fiscal Year: 2006
    ..The studies will initially focus on the effects of halothane; however, when significant effects are observed, the effects of isoflurane and sevoflurane will also be explored. ..
  21. PHARMACOGENETICS AND RESPONSE TO THERAPY IN OLDER ADULTS
    SUSAN HECKBERT; Fiscal Year: 2000
    ..This project will incorporate advances in molecular biology in the study of response to drug therapy for common conditions, with the goal of improving clinical care of the elderly. ..
  22. EBP Leadership Summit: Improving health outcomes for high risk children and teens
    Bernadette Melnyk; Fiscal Year: 2007
    ..S. to improve health outcomes for our nation's children and adolescents. [unreadable] [unreadable] [unreadable] [unreadable]..
  23. Pneumedoreductive Surfacant - New Therapy for Emphysema
    Edward Ingenito; Fiscal Year: 2004
    ..abstract_text> ..
  24. INHALED NO IN PREVENTION OF CHRONIC LUNG DISEASE
    Scott Lorch; Fiscal Year: 2004
    ..In summary, this clinical trial will assess the efficacy and safety of inhaled nitric oxide for amelioration of a major disease of premature infants. ..
  25. Novel Strategies Targeting Acute Exacerbation of COPD
    Richard Albert; Fiscal Year: 2007
    ..This information will, at the same time, also provide information regarding the pathobiology of COPD exacerbations. ..
  26. A Novel Approach to Identify Smooth Muscle Relaxants
    JAMES HARTMAN; Fiscal Year: 2001
    ..In addition, a potent smooth muscle relaxant may have applications in the other large therapeutic areas such as hypertension, pre-term labor, and bladder spasmaticity leading to incontinence. ..
  27. Development of Alpha-1 Antitrypsin Gene Therapeutic as Treatment for COPD
    Jonathan Sanders; Fiscal Year: 2005
    ..abstract_text> ..
  28. Distal Lung Inflammation Effect on Asthma Exacerbations
    Donald Tashkin; Fiscal Year: 2008
    ..This study has the potential to clarify the contribution of the "silent zone" to the persistent morbidity encountered with asthma. ..
  29. LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    Donald Tashkin; Fiscal Year: 2002
    ..All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
  30. SCLERODERMA LUNG STUDY
    Donald Tashkin; Fiscal Year: 2003
    ..abstract_text> ..
  31. Obstruction in Asthma--Role of Airway Closure
    Andrew Jackson; Fiscal Year: 2003
    ..If we can demonstrate that asthma includes a major component of airway closure, this may very well identify a new direction for future research, which may lead to entirely new treatment approaches. ..
  32. Regulation of Nrf2 pathway during COPD pathogenesis
    Shyam Biswal; Fiscal Year: 2009
    ..This application focuses on deciphering the regulatory role of Nrf2 in the pathogenesis of COPD. Positive results will help in development of therapies targeting Nrf2 pathway. ..
  33. MECHANISMS OF LUNG BETA2AR FUNCTION IN TRANSGENIC MICE
    DENNIS MCGRAW; Fiscal Year: 2003
    ..This includes the mentor ship of Drs. Liggett and Whitsett, and an Advisory committee composed of established investigators with extensive experience in raining physicians scientists. ..
  34. POCKET NEBULIZER
    A Sipin; Fiscal Year: 1990
    ..Phase II is planed for the development to readiness for production of the improved devices for administration of therapeutic aerosol. A large market is foreseen...
  35. COPD Clinical Research Network
    Frank Sciurba; Fiscal Year: 2007
    ..We believe that our strong clinical trials experience, extraordinary access to research interested subjects and basic and clinical science record would make us strong participants in the COPD-CRN. ..
  36. Altered cAMP Regulation of CD40L in Asthma
    Denise Wingett; Fiscal Year: 2005
    ..abstract_text> ..
  37. SYMPATHETIC TRANSMITTER REG OF IMMUNE RESPONSE
    Barbara Kruszewska; Fiscal Year: 1999
    ..Second, many norepinephrine ligands are currently used in drug therapy (i.e., beta blockers, bronchodilators), and these studies will provide insight into the potential consequences of such therapy on immunity. ..
  38. AMINOSTEROL COMPOUNDS AS THERAPEUTICS FOR ASTHMA
    Roy Levitt; Fiscal Year: 2000
    ..abstract_text> ..
  39. ANESTHESIA AND AIRWAYS
    Keith Jones; Fiscal Year: 2005
    ..Also, pathways that control calcium sensitivity are a potential target for therapeutic manipulation, and exploration of these systems and anesthetic effects may facilitate the development of novel bronchodilators. ..
  40. Response to Beta2-Agonists in Acute Severe Asthma
    Nicola Hanania; Fiscal Year: 2008
    ..abstract_text> ..
  41. ASTHMA CLINICAL RESEARCH NETWORK (ACRN)
    Stephen Peters; Fiscal Year: 2007
    ....
  42. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 2001
    ....
  43. ASTHMA CLINICAL RESEARCH NETWORK
    ROBERT LEMANSKE; Fiscal Year: 2002
    ....
  44. LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    Nicholas Anthonisen; Fiscal Year: 2002
    ..All ten of the original LHS clinical centers plan to participate. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
  45. GENETIC REGULATION OF IMMUNE MATURATION IN ASTHMA
    Fernando Martinez; Fiscal Year: 2001
    ....
  46. Clinical Trial of Acid Reflux Therapy in Asthma
    Robert Wise; Fiscal Year: 2007
    ..Pre-specified subgroup analyses will be conducted to determine if there are clinical or demographic characteristics that predict benefit from treatment of GERD in asthma. ..
  47. CYTOKINE DYSREGULATION, VIRUSES, AND CHILDHOOD ASTHMA
    ROBERT LEMANSKE; Fiscal Year: 2001
    ..The results of these studies will provide information that will be a major step forward in our understanding of the relative influence that genetic and environmental risk factors on the development of childhood asthma. ..
  48. Mitochondria and surgical myopreservation in aging
    Arshad Jahangir; Fiscal Year: 2006
    ..This is especially relevant for cardiac surgery in the elderly, with the ultimate goal of limiting post-bypass pump failure. ..
  49. MECHANISMS OF RHINOVIRUS INDUCED ASTHMA
    William Busse; Fiscal Year: 2002
    ..The proposed studies will provide new evidence as the mechanisms by which RV-infected epithelial cells cause granulocytic bronchial inflammation and asthma exacerbations. ..
  50. HAEMOPHILUS ANTIGEN REGULATION OF INFLAMMATION IN COPD
    Sanjay Sethi; Fiscal Year: 2003
    ..Identification of the integral bacterial and host components that contribute to immune-mediated inflammation in COPD will ultimately lead to novel therapeutic strategies to alter disease progression and improve outcome in COPD. ..
  51. CARE Network--St. Louis Center
    Robert Strunk; Fiscal Year: 2008
    ..End of abstract.) [unreadable] [unreadable]..
  52. Strategies to Improve COPD Management
    Richard Casaburi; Fiscal Year: 2007
    ..These studies should have immediate impact on treatment strategies for large poor-prognosis subgroups of COPD patients. ..
  53. Interferons Modulate Airway Smooth Muscle Growth
    Reynold Panettieri; Fiscal Year: 2008
    ....
  54. Mechanisms of VEGF modulation of smooth muscle function
    Reynold Panettieri; Fiscal Year: 2009
    ..abstract_text> ..
  55. Innate Immunity and exacerbations of COPD
    Sanjay Sethi; Fiscal Year: 2009
    ..The overall goal of this research is to identify specific aspects of the innate defense of the lung that determine the frequency of exacerbations in COPD that will serve as potential therapeutic targets to reduce exacerbations. ..
  56. SCLERODERMA LUNG STUDY
    Robert Wise; Fiscal Year: 2003
    ..abstract_text> ..
  57. Treatment of Severe Persistent Asthma
    ROBERT LEMANSKE; Fiscal Year: 2007
    ..abstract_text> ..
  58. Obesity, Inflammation and Response to Therapy in Asthma
    EVERETT RAND SUTHERLAND; Fiscal Year: 2010
    ..End of Abstract) ..
  59. CHROMOSOME 5Q GENE VARIANTS AND ASTHMA-RELATED TRAITS
    Fernando Martinez; Fiscal Year: 2004
    ..This will allow to better understand the genetic influence that determine asthma risk. ..
  60. INNATE IMMUNITY IN HEART, LUNG, AND BLOOD DISEASE
    Fernando Martinez; Fiscal Year: 2003
    ..abstract_text> ..
  61. Severe Asthma From Respiratory Infections
    William W Busse; Fiscal Year: 2010
    ..These studies will provide new insights into the mechanisms of asthma, particularly severe disease, and possibilities of new approaches to treatment. ..